Latest news for Capha Pharmaceuticals (OTC:FPSUF) Stock

Capha Pharmaceuticals Inc is a Canada-based company principally operating in the pharmaceutical industry. The company produces and distributes products in Canada and the United States of America.

CAPHA PHARMA INC ORD by Capha Pharmaceuticals Inc.

Capha Pharmaceuticals Inc

Earnings

News

CenterPoint Energy Provided An Update On Its Response To Hurricane Beryl; Expects To Take Action To Protect Its Electrical Assets By Nearly Doubling The Size Of Its Vegetation Management Crews And Targeting Higher Risk Vegetation

Stanley Black & Decker shares are trading higher after the company reported better-than-expected Q2 financial results. Additionally, the company revised its FY24 adjusted EPS forecast upward.

WIIM

AFRM

Affirm Holdings shares are trading higher after B of A Securities upgraded the stock from Neutral to Buy.

JBLU

JetBlue Airways shares are trading higher after the company reported better-than-expected Q2 financial results.

JP Morgan analyst Jamie Baker downgrades Frontier Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) from Neutral to Underweight.

Downgrades

Analyst Ratings

ULCC

JP Morgan Downgrades Frontier Group Holdings to Underweight

Guidance

CenterPoint Energy Reiterates 2024 Adjusted EPS Guidance Of $1.61-$1.63 Vs. Consensus of $1.62

JP Morgan analyst Eric Joseph downgrades Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) from Neutral to Underweight and announces $8 price target.

Price Target

NVAX

JP Morgan Downgrades Novavax to Underweight, Announces $8 Price Target

CenterPoint Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNP#NYSE">CNP</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.32 by 12.5 percent. The company reported quarterly sales of $1.905 billion which beat the analyst consensus estimate of $1.887 billion by 0.96 percent. This is a 1.60 percent increase over sales of $1.875 billion the same period last year.

Earnings Beats

CenterPoint Energy Q2 2024 Adj. EPS $0.36 Beats $0.32 Estimate, Sales $1.905B Beat $1.887B Estimate

Outlook
Third Quarter 2024
The Company expects net sales to increase between 25% and 28% compared to the prior year. Foreign currency translation is expected to have an approximately 1 percentage point favorable impact.
Adjusted EBITDA margin is expected to be between 20% and 21%. Non-GAAP diluted earnings per share are expected to be in the range of $3.00 to $3.30.

ZBRA

Zebra Technologies Expects Q3 Net Sales Growth Of 25%-28% YoY Vs $1.191B Est, Adj EPS Of $3.00-$3.30 Vs $3.06 Est

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) with a Buy and maintains $18 price target.

Reiteration

ARQT

Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $18 Price Target

Revised Full Year 2024
The Company has raised its guidance for the full year. It now expects net sales growth between 4% and 7% compared to the prior year. Foreign currency translation is expected to have a 50 basis point favorable impact.
Adjusted EBITDA margin is now expected to be between 20% and 21%. Non-GAAP diluted earnings per share are now expected to be in the range of $12.30 to $12.90. This assumes an adjusted effective tax rate of approximately 17%.
Free cash flow is now expected to be at least $700 million.

Zebra Technologies Now Expects FY24 Net Sales Growth of 4%-7% (Prior 1%-5%) Vs $4.776B Est, Adj EPS of $12.30-$12.90 (Prior $11.25-$12.25) Vs $11.99 Est

The collaboration aims to modernize TDC Net&#39;s IT infrastructure, improve their customer experience, and help them optimize IT and operational service costs.
&nbsp;

INFY

Infosys Reveals Collaboration With Danish Digital Infrastructure And Connectivity Provider TDC Net

HC Wainwright &amp; Co. analyst Scott Buck reiterates Transcat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNS#NASDAQ">TRNS</a>) with a Buy and maintains $156 price target.

TRNS

HC Wainwright & Co. Reiterates Buy on Transcat, Maintains $156 Price Target

Zebra Technologies Q2 2024 Adj. EPS $3.18 Beats $2.81 Estimate, Sales $1.217B Beat $1.182B Estimate

The Democratic party&#8217;s campaign against Republican Donald Trump has gained momentum with Vice President Kamala Harris&#8217; addition to the ticket. However, a few key lawmakers are yet to extend their endorsement.
What Happened: Out of the 35 competitive races that will determine the control of the U.S. House of Representatives in the upcoming November 5 election, 12 Democratic incumbents or challengers have not endorsed Harris, Reuters reported on Tuesday. These lawmakers are positioning themselves as independent decision-makers who prioritize their constituents over national politics.
Maine Representative Jared Golden (D-Maine) one of the 12, plans to evaluate Harris&#8217; proposed policies before deciding whether to support her.
He stated, &#8220;Our choice in leaders should never be a knee-jerk decision driven solely by party loyalty.&#8221; 
Golden is among six House Democrats who voted in favor of a Republican resolution condemning the Biden administration&#8217;s handling of migrants at the Mexico border. These Democrats are from Alaska, Colorado, Maine, North Carolina, Texas, and Washington state.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/40001633/scaramucci-i-agree-with-every-single-thing-trump-has-said-on-bitcoin?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Scaramucci: &#8216;I Agree With Every Single Thing&#8217; Trump Has Said On Bitcoin</a>
Despite some hesitation, the wider Democratic Party has quickly rallied behind Harris since Biden endorsed her on July 21. Harris&#8217; campaign reported over $200 million in donations and 170,000 volunteers in the first week. Opinion polls show her closing the gap on Trump, reshaping the race and potentially boosting down-ballot candidates.
However, the need for support from the House is crucial. If Democrats win control of the House, they could either help drive Harris&#8217; agenda forward if she wins or serve as a bulwark against Trump if he prevails.
Why It Matters: A recent WSJ poll indicated that while <a href="https://www.benzinga.com/news/24/07/39996908/trump-vs-harris-new-poll-shows-ex-president-leading-democratic-candidate-by-a-narrow-margin-but-vice">Trump is leading </a>Harris by a narrow margin, the incumbent VP is faring much better than President Joe Biden who stepped out of the presidential race.
Harris&#8217; infectious laughter has <a href="https://www.benzinga.com/markets/cannabis/24/07/40001997/kamala-harriss-hearty-laugh-why-does-it-bother-donald-trump-and-his-followers-so-much">become a point of contention</a> in political circles since she assumed office as Biden&#8217;s VP in January 2021. Critics, led by Trump, have exploited her laughter, calling it a liability and using it to undermine her.
On the other hand, Harris&#8217; campaign has seen a <a href="https://www.benzinga.com/news/24/07/40002603/kamala-harris-raises-200m-in-a-week-66-of-that-money-is-from-donors-reveals-campaign-manager-a-peopl">significant boost since Biden&#8217;s </a>endorsement, raising $200 million and adding 170,000 new volunteers in a week. 66% of this funding came from new donors, indicating a strong people-powered campaign.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40003111/potential-kamala-harris-vp-pick-pete-buttigieg-says-voters-are-worried-about-age-and-acuity-of-presi?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Potential Kamala Harris VP Pick Pete Buttigieg Says &#8216;Voters Are Worried About Age And Acuity Of President Trump&#8217;</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Politics

General

As Kamala Harris Gains Momentum Against Trump, Not Every Democratic Lawmaker Is By Her Side Yet

As previously disclosed, on May 7, 2024, Alaska and Hawaiian certified substantial compliance with a request for additional information and documentary material (the &ldquo;Second Request&rdquo;) received from the Antitrust Division of the Department of Justice (the &ldquo;DOJ&rdquo;) on February 7, 2024 in connection with the DOJ&rsquo;s review of the Merger, which triggered the start of a Review Period (as defined below) under a timing agreement Alaska and Hawaiian entered into with the DOJ on March 27, 2024.
Pursuant to the timing agreement, Alaska and Hawaiian agreed, among other things, not to consummate the Merger before 90 days following the date on which both parties certified substantial compliance with the Second Request (the &ldquo;Review Period&rdquo;) unless they received written notice from the DOJ prior to the end of the Review Period that the DOJ has closed its investigation of the Merger. The Review Period was previously scheduled to expire on August 5, 2024.

On July 29, 2024, Alaska And Hawaiian Agreed With DoJ To Extend Review Period Until 12:01 A. M. Eastern Time On August 15, 2024 - Filing

Needham analyst Mike Matson reiterates Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Buy and maintains $90 price target.

HOLX

Needham Reiterates Buy on Hologic, Maintains $90 Price Target

Tech

Infosys Partners With Danish Digital Infrastructure Provider, TDC Net To Boost Digital Transformation

&quot;As we execute on our strategy to return to profitability, we remain focused on delivering on our near-term financial goals. In the second half, we expect sequential year-over-year unit revenue momentum to bolster the top-line, supported by our&nbsp;$300 million&nbsp;of revenue initiatives and the continuing normalization of competitive capacity in our core geographies,&quot; said Marty St. George.
&quot;We&#39;ve faced a number of unit cost headwinds this year, including approximately one point of pressure from the change in recognition of Pratt &amp; Whitney compensation and one point from lower capacity than planned, yet we are maintaining our full year CASM-ex Fuel(1)&nbsp;guidance&nbsp;and now expect it be in the range of&nbsp;6.5%&nbsp;-&nbsp;8.5%&nbsp;for the full year,&quot; said Ursula Hurley.&nbsp;

JetBlue Expects Q3 Revenue To Decline (5.5%) - (1.5%) Y/Y; Now Sees FY24 Revenue To Decline (6.0%) - (4.0%) Vs Prior Forecast Of Down Low Single Digits

Nomura Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMR#NYSE">NMR</a>) reported quarterly earnings of $0.14 per share. This is a 180 percent increase over earnings of $0.05 per share from the same period last year. The company reported $2.92 billion in sales this quarter. This is a 14.67 percent increase over sales of $2.54 billion the same period last year.

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Capha Pharmaceuticals

News

Latest news for Capha Pharmaceuticals (OTC:FPSUF) Stock